InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,623.23
(
-0.20%
)
US TECH 100
18,934.80
(
-0.03%
)
Dow Jones
41,534.45
(
-0.17%
)
Brent Oil
72.35
(
-1.33%
)
Bitcoin
60,213.43
(
-0.15%
)
Post# of 253146
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120458
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 146061

Friday, 08/10/2012 1:13:32 PM

Friday, August 10, 2012 1:13:32 PM

Post# of 253146
FDA approves Lucentis for DME, but only at 0.3mg dose:

http://finance.yahoo.com/news/fda-approves-lucentis-ranibizumab-injection-164400367.html

The FDA-approved dose for AMD and RVO is the higher 0.5mg; thus, although the addressable patent pool for DME is at least half as large the patient pool for wet AMD, the potential sales are somewhat lower than that due to the smaller dose.

In the EU, Lucentis was approved for DME in Jan 2011 at the 0.5mg dose (#msg-58523789).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up